NCT00141284: An Open Label Study To Evaluate The Safety and Kinetics of Nelfinavir in Subjects With HIV and Hepatitis C |
|
|
| Completed | 4 | 12 | US, Canada | nelfinavir 1,250 mg twice daily, Zidovudine 300 mg twice daily, Lamivudine 150 mg twice daily | Pfizer | HIV Infection, Hepatitis C | 12/06 | 12/06 | | |
